



Date: 10<sup>th</sup> February, 2025

To,  
Department of Corporate Services  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 531569

Sub: Press Release on Unaudited Financial Results for the Third Quarter Year ended December 31, 2024.

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find enclosed the press release on Unaudited Financial Results for the Third Quarter Year ended December 31, 2024.

Kindly take the above information on your records.

Thanking You,  
Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam  
Company Secretary Cum Compliance Officer

## Press Release

### Sanjivani Paranteral Limited reported a strong performance for the quarter ended 31<sup>st</sup> December 2024

**Mumbai, 10 February 2025:** Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

**Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said,** “We are pleased to report a steady performance in Q3 FY25, reflecting our continued focus on operational efficiency and sustainable growth. Total income stood at ₹173.5 million, marking a 16% YoY growth, while our PAT rose by 15% YoY to ₹19.0 million, driven by improved profitability and strategic cost management. Looking ahead, we remain focused on scaling our operations, enhancing product innovation, and expanding market reach. With a robust pipeline and operational efficiencies in place, we are confident in sustaining growth momentum and driving long-term value for our shareholders.”

#### Financial Summary:

##### **Q3 FY25:**

- Revenue from operation grew 15.9% YoY to INR 173.5 mn.
- EBITDA margin stood at 16.5% (up 171bps YoY).
- Profit After Tax (PAT) stood at 19.0 mn. (up 15.0% YoY).

Particulars (Rs. in mn.)	Q3FY25	Q3FY24	Q2FY25	9M FY25	9M FY24	FY24
Total Income	176.6	152.2	185.2	527.0	420.1	549.3
Gross Profit	77.3	72.4	76.2	216.1	184.8	264.4
Gross Margin (%)	44.6%	48.4%	42.0%	41.6%	44.5%	48.6%
EBITDA incl. other income	28.6	22.1	32.4	85.3	65.5	87.6
EBITDA Margin (%)	16.5%	14.8%	17.9%	16.4%	15.8%	16.1%
PBT	25.1	19.0	29.2	77.0	56.9	75.7
PBT Margin %	14.2%	12.5%	15.7%	14.6%	13.5%	13.8%
PAT	19.0	16.5	23.0	59.1	49.1	61.7
PAT Margin (%)	10.7%	10.9%	12.4%	11.2%	11.7%	11.2%
EPS (in INR)	1.62	1.65	1.96	5.06	4.91	5.28

#### **Segment-wise Performance:**

- **Injectables:** Revenue grew 34.8% YoY to Rs. 129.2mn.
- **Oral:** Revenue grew 1.4% YoY to INR 34.1mn.

- **Nutraceuticals:** Revenue grew 493.3% YoY to INR 10.2mn.

**Market-Wise Performance:**

- Exports (incl. Exports incentives) constitute 84.9% of total revenue while domestic constitutes 15.1%.
- Core markets of CIS, Latin America, Middle East & Africa and Southeast Asia accounted for 84.9% to INR 147mn.

**9M FY25:**

- Revenue from operation grew 25.0% YoY to INR 519.2 mn.
- EBITDA margin stood at 16.4% (up 66bps YoY).
- Profit After Tax (PAT) grew 20.4% YoY to INR 59.1 mn.

**Segment-wise Performance:**

- **Injectables:** Revenue grew 11.9% YoY to Rs. 281.0mn.
- **Oral:** Revenue grew 36.0% YoY to INR 210.6mn.
- **Nutraceuticals:** Revenue grew 694.5% YoY to INR 27.6mn.

**Market-Wise Performance:**

- Core markets of CIS, Latin America, Middle East & Africa and Southeast Asia accounted for 76.5% of 9MFY25 revenue to Rs 397.0 mn.

**Pritesh Jain**

Sanjivani Paranteral  
Chief Financial Officer  
[pritesh.jain@sanjivani.co.in](mailto:pritesh.jain@sanjivani.co.in)

**Jill Chandrani**

S-ancial Technologies  
[jill@s-ancial.com](mailto:jill@s-ancial.com)

**DISCLAIMER:**

*Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*